Kami Maddocks, MD, Ohio State University Medical Center

home / authors / kami-maddocks,-md,-ohio-state-university-medical-center

Articles

Closing Thoughts on Treatment of R/R DLBCL

Closing Thoughts on Treatment of R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Improving Outcomes in Patients With R/R DLBCL

Improving Outcomes in Patients With R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Emerging Therapies for R/R DLBCL

Emerging Therapies for R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Safety and Efficacy of Oral Agents in R/R DLBCL

Safety and Efficacy of Oral Agents in R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

Treatment of R/R DLBCL: CD19-Directed Therapy vs CAR T

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

CD19-Directed Therapies for Treatment of R/R DLBCL

CD19-Directed Therapies for Treatment of R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

CAR T in R/R DLBCL: Safety and Patient Selection

CAR T in R/R DLBCL: Safety and Patient Selection

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

ASCO 2020 Data: CAR T in R/R DLBCL

ASCO 2020 Data: CAR T in R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Role of CAR T-cell Therapy in R/R DLBCL

Role of CAR T-cell Therapy in R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Treatment in Transplant-ineligible R/R DLBCL

Treatment in Transplant-ineligible R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Prognosis of R/R DLBCL

Prognosis of R/R DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Standard of Care for Treatment of DLBCL

Standard of Care for Treatment of DLBCL

Nathan H. Fowler, MD, MD Anderson Cancer Center;John P. Leonard, MD, Weill Cornell Medicine;Matthew A. Lunning, DO, FACP, University of Nebraska Medical Center;Kami Maddocks, MD, Ohio State University Medical Center
July 15th 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data